

1   **Official Title: “Does Intravenous Lactated Ringer’s Solution Raise**  
2   **Serum Lactate?”**

3

4   **NCT number:** NCT02950753

5

6   **Date approved by IRB:** Nov 17, 2016

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

## **Introduction**

Since “early goal-directed therapy,” early recognition of septic shock using the serum lactate has become standard of care [1-4]. Indeed, the central place of lactate in sepsis care has been promoted by the Surviving Sepsis campaign, and it is now backed by financial incentives for hospitals with its adoption as a CMS Core Measure [5].

In this context, it is important to elucidate all possible causes of hyperlactatemia. Previous studies have shown that serum lactate increases in all shock states, not just septic shock [6]. Furthermore, lactate has also been shown to increase from albuterol [7], anti-retroviral medications, metformin, propofol, and alcohols [8].

According to Surviving Sepsis Guidelines, patients diagnosed with septic shock should receive 30 mL/kg of crystalloid solution within three hours [9]. One commonly used crystalloid, Lactated Ringer’s solution (LR), contains 28 mmol/L of racemic lactate in the form of sodium lactate. While lactate is rapidly metabolized by the liver and kidney, aggressive fluid resuscitation with LR may transiently raise serum lactate, potentially confounding the interpretation of this test.

There has only been one trial looking at the question of whether administration of LR raises serum lactate. That study did not show a difference in lactate levels in those receiving LR versus those receiving alternative crystalloid solutions. However, that study used only 1 liter of LR delivered over one hour [10]. As mentioned above, patients in

septic shock are mandated to receive 30 mL/kg of crystalloid solution, and the fluids are typically given at a rate faster than 1 liter per hour. Therefore, when LR is given at a volume and rate more similar to what is done for septic shock patients, LR may have an effect on serum lactate level that was not identified in the previous study.

Thus, we propose a double-blind, randomized controlled trial to investigate whether the administration of intravenous LR at 30 mL/kg increases levels of serum lactate. As our study compares the effect of NS and LR, it lends itself easily to secondarily investigating changes in sodium (Na), chloride (Cl), and pH in the NS group compared to the LR group.

## **Materials and Methods**

### **Study Design and Setting**

This will be a double-blind, randomized controlled trial performed on a group of healthy volunteers, made up primarily of family, friends, and colleagues of the investigators.

All subjects will be healthy volunteers aged 18 years or older. Healthy volunteers are defined as subjects with no acute symptoms who meet none of the following exclusion criteria: pregnant, breast-feeding, prisoners, history of conditions associated with fluid overload (congestive heart, renal, or hepatic failure), baseline serum lactate level  $>2.2$  mmol, and baseline creatinine  $>1.5$  mg/dL.

70

71 All volunteers will fill out a short data collection form assessing their age, weight,  
72 gender, and medical history. All volunteers will signed a written consent, approved by the  
73 IRB.

74

75 A random-number generator will be used to assign each subject to either LR or NS. After  
76 assignment, a pharmacist with no role in data collection prepared the fluids in a locked  
77 room. The pharmacist will use an opaque black bag to obscure the fluids. The subjects  
78 will then receive 30 mL/kg rounded to the nearest 100 mL of the solution to which they  
79 were randomized.

80

81 An investigator will place an 18 gauge IV in one upper extremity, and an initial serum  
82 lactate and electrolyte panel will be drawn, measured using the i-STAT 1 analyzer  
83 (Abbott Point of Care, Princeton, NJ). Fluids will be administered as a rapid bolus via  
84 pressure bag. Post-treatment blood will be drawn from the contralateral upper extremity  
85 five minutes after the conclusion of the IV fluid administration.

86

## 87 **Outcomes**

88

89 The primary outcome will be the difference in change in serum lactate levels between the  
90 LR and NS groups. Secondly, we will compare the change in lactate within each group  
91 (before and after treatment), and we will compare the change in pH, creatinine,  
92 bicarbonate, Na, and Cl levels between NS and LR groups.

93

## 94 **Data Analysis**

95

96 We powered the study as follows. A sample size of 30 achieves 80% power to detect a  
97 difference of 0.5 mmol/L in the mean change in lactate between the NS and LR groups  
98 assuming a standard deviation of differences of 0.5 and an alpha of 0.05. We chose the  
99 value of 0.5 mmol/L by clinical gestalt based on what we consider a clinically significant  
100 difference in lactate levels. Before and after treatment lactate levels will be compared  
101 within each group using paired t-tests. We will compare the change in mean lactate and  
102 the change in other variables (pH, creatinine, bicarbonate, Na, and Cl) between the LR  
103 and NS groups using two-tailed t-tests.

104

## 105 **References**

- 106 1. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of  
107 severe sepsis and septic shock. *N Engl J Med*. 2001; 345 (19): 1368–77.
- 108 2. Process Investigators, Yealy DM, Kellum JA, et al, A randomized trial of protocol-  
109 based care for early septic shock. *N Engl J Med*. 2014;370:1683–1693.
- 110 3. Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation  
111 for septic shock. *N Engl J Med*. 2015;372:1301–1311.
- 112 4. ARISE Investigators, Anzics Clinical Trials Group, Peake SL, et al. Goal-directed  
113 resuscitation for patients with early septic shock. *N Engl J Med*. 2014;371:1496–1506.
- 114 5. Centers for Medicare & Medicaid Services. CMS specifications manual version 5.2a.  
115 Available at:

<https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775749207>. Accessed August 22, 2017

6. Cecconi M., De Backer D., Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. *Intensive Care Med.* 2014; 40:1795–815.
7. Zitek T, Cleveland N, Rahbar A, et al. Effect of Nebulized Albuterol on Serum Lactate and Potassium in Healthy Subjects. *Acad Emerg Med.* 2016; 23(6):718-21.
8. Kraut, JA. Madias NE. Lactic Acidosis. *N Engl J Med.* 2014;371:2309-19.
9. Dellinger R, Levy M, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for the management of severe sepsis and septic shock 2012. *Crit Care Med.* 2013; 41: 580–637.
10. Didwania A, Miller J, Kassel D, et al. Effect of intravenous lactated Ringer's solution infusion on the circulating lactate concentration: Part 3. Results of a prospective, randomized, double-blind, placebo-controlled trial. *Crit Care Med.* 1997; 25(11):1851-4.